Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.38 |
| ▸ | AXL | P30530 | 1/20 | 0.37 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.37 |
| ▸ | MERTK | Q12866 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.35 |
| ▸ | FEN1 | P39748 | 1/20 | 0.35 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.34 |
| ▸ | ACACB | O00763 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21503699 | 1.00 | LIPE (0.43) | LIPECHRNB2CHRNA4TRPV4AXL | |
| SCHEMBL26709805 | 0.85 | CHRNB2 (0.46) | LIPECHRNB2CHRNA4TRPV4AXL | |
| SCHEMBL21503666 | 0.82 | CHRNB2 (0.53) | LIPECHRNB2CHRNA4TRPV4ALOX5AP | |
| SCHEMBL26703986 | 0.82 | CHRNB2 (0.53) | LIPECHRNB2CHRNA4TRPV4ALOX5AP | |
| SCHEMBL21503695 | 0.81 | CHRNB2 (0.45) | LIPECHRNB2CHRNA4TRPV4AXL | |
| SCHEMBL26933208 | 0.81 | CHRNB2 (0.45) | LIPECHRNB2CHRNA4TRPV4AXL | |
| SCHEMBL23207725 | 0.81 | CHRNB2 (0.45) | LIPECHRNB2CHRNA4TRPV4AXL | |
| SCHEMBL21503700 | 0.80 | CHRNB2 (0.45) | LIPECHRNB2CHRNA4TRPV4AXL | |
| Hydrochloric Acid SCHEMBL23167958 | 0.79 | CHRNB2 (0.47) | LIPECHRNB2CHRNA4TRPV4AXL | |
| Hydrochloric Acid SCHEMBL23167961 | 0.79 | CHRNB2 (0.47) | LIPECHRNB2CHRNA4TRPV4AXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2023-10-05 | — | — | US | disclosed |
| US-11572364-B2 | Pteridinone compounds and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572364-B2 | Pteridinone compounds and uses thereof | DPYD, PKD1, TYMP | LIPE 4835/4885CHRNB2 4666/4885CHRNA4 4806/4885 |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | DPYD, PKD1, TYMP | LIPE 4835/4885CHRNB2 4666/4885CHRNA4 4806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.